The group further warns that even if the five potential vaccines turn out to be sufficiently safe and effective-an unlikely scenario-the coming year would still be marked by the public health crisis because 61% of the world's population would likely not have a vaccine until at least 2022.
The Phase I and II results had shown promise, G V Prasad, co-chairman of Dr Reddy's, was cited in the RDIF statement as saying.
FILE - A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020.
Serum Institute of India will begin the trial of another COVID-19 vaccine candidate developed by Novavax in next month. An inactivated whole virion candidate vaccine (BBV152) for SARS-CoV-2 has been developed by Bharat Biotech International Ltd using the virus isolate provided by ICMR-National Institute of Virology (NIV), Pune.
The adenovirus-based viral vector vaccine is yet to complete a large-scale clinical trial but has been approved by the Russian government. Immunogenicity testing is in progress.
Among the half of Americans who say they would not get a vaccine, 76pc said concern about side effects was a major reason why they would definitely or probably not get it.
A DNA vaccine has been developed by Cadila Healthcare Ltd. Pre-clincial toxicity studies were conducted on small animals: mice, rats, rabbits and guinea pigs.
JPMorgan analyst Cory Kasimov said that although the vaccine candidate appears to be showing a "promising profile", he still wants to see "the Phase 3 results with mRNA-1273, which are anticipated sometime this fall, to see how the data evolves".
The remaining 2.6 billion doses have been bought by or promised to developing countries including India, Bangladesh, China, Brazil, Indonesia and Mexico, among others.
"We already face challenges with vaccine acceptance for many proven vaccines", World Health Organization chief Tedros Adhanom Ghebreyesus said in pre-recorded comments, as he spoke about the push to rapidly develop vaccines. The ICMR and SII have also partnered for clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine developed by Novavax from the US.
However, scientists worldwide have auctioned against the use of a coronavirus vaccine that has not fully cleared safety and efficacy trials.
USA government officials say a vaccine candidate must show it is at least 50 percent more effective than a placebo, before the Food and Drug Administration (FDA) would consider it for approval.